Inhibrx
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11025 N Torrey Pines Rd Ste 140, La Joll...Phone Number
(858) 795-4220Website
www.inhibrx.comRevenue
-Stock Symbol
INBXIndustry
About Inhibrx
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric and gastroesophageal adenocarcinoma cancer, renal cell carcinoma, and urothelial cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Explore more
Inhibrx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Inhibrx
Compare insights from companies similar to Inhibrx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Inhibrx Tech Stack
A closer look at the technologies used by Inhibrx
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Inhibrx
Sign Up For FreeTo access detailed company insights
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or m... Read More
